The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 24% and continues to increase significantly because of the rise in obesity and other metabolic disorders.1 Further, the number of patients quickly progressing to more severe stages of the disease is also increasing; in the US alone, non-alcoholic steatohepatitis (NASH) is already considered the second most common indication for liver transplantation, with prevalent NASH cases forecasted to increase to 27 million by 2030.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: